last

Genzyme Announces Results of Clinical Trial of Hylastan

CAMBRIDGE, Mass., July 05, 2007 /PRNewswire-FirstCall/ --Genzyme Corp. today announced top-line results from a pivotal studyinvestigating the safety and efficacy of hylastan in treating painin patients with osteoarthritis (OA) of the knee. Hylastan is beingdeveloped within Genzyme's program to introduce aviscosupplementation product that can be delivered through a singleknee injection. T...

In Vitro and In Vivo Data Show Alfacell's Onocanse is Active Against Naive and Chemoresistant Neuroblastoma Cells

Pre-Clinical Results Demonstrate Potential of ONCONASE forTreatment of Neuroblastoma BLOOMFIELD, N.J., June 27, 2007 /PRNewswire-FirstCall/ --Alfacell Corporation today announced that new data show ONCONASE,the company's lead drug candidate, is active against naive andchemoresistant neuroblastoma cells. The pre-clinical in vitro and in vivo data published in CancerLetters (2007; Vo...

Neuroblastoma Expert Reviews Progress and Challenges in Fighting Difficult Pediatric Cancer

PHILADELPHIA, June 25, 2007 /PRNewswire-USNewswire/ -- Childhoodcancers are fortunately rare, but among them, neuroblastoma is aspecial case, accounting for 7 percent of all childhood cancers,but 15 percent of childhood cancer deaths. It typically occurs as asolid tumor in the abdomen, but also in the neck, chest, andpelvis, developing in the network of the body's sympathetic nervoussyst...

Antisense Pharma: Promising Phase IIb Results of Targeted Therapy with AP 12009 in Recurrent Anaplastic Astrocytoma

CHICAGO and REGENSBURG - June 21, 2007 - “In anaplasticastrocytoma, AP 12009 as a monotherapy is actually clearly superiorto temozolomide,” Prof. Albert Wong, M.D., StanfordUniversity, California, U.S.A. commented on the international PhaseIIb study with the TGF-beta 2-inhibitor AP 12009, under developmentby Antisense Pharma. Prof. Wong discussed the results of the studyin th...

Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)

Phase II GBM study presented at ASCO with cediranib - a selectiveVEGF signaling inhibitor - shows over a quarter of patients aliveand progression- free at six months(1) CHICAGO, June 04, 2007 /PRNewswire/ -- Data for theinvestigational agent cediranib (AZD2171) were presented today atthe annual meeting of the American Society of Clinical Oncology(ASCO) from a study in patients with recurr...

Pharmexa A/S (DK) - Long lasting immune response and survival to RAS vaccine

HORSOLM, Denmark, June 4, 2007-Professor Trond Buanes today gavea presentation titled "RAS peptide vaccination in resectedpancreatic cancer patients - persistence of anti tumour responseand long term survival" at ASCO's (American Society of ClinicalOncology) annual cancer meeting. A follow-up study of 23 resected pancreatic cancer...

Merck at ASCO 2007: Encouraging Results in Progression-Free Survival in Patients With Aggressive Brain Tumors (glioblastoma) Using Cilengitide in Phase I/IIa Study

Abstracts: 2000, 2002 CHICAGO/DARMSTADT, Germany, June 4, 2007 – Results of aPhase I/IIa study presented today at the American Society ofClinical Oncology (ASCO) annual meeting in Chicago demonstrate theclinical activity of cilengitide in patients with newly diagnosedglioblastoma – a particularly aggressive form of brain tumor.Cilengitide i...

Soliris Effective in PNH Patients With History of Aplastic Anemia and Myelodysplastic Syndromes

- Analysis of Phase III Data Presented at ASCO - CHICAGO, June 04, 2007 /PRNewswire-FirstCall/ -- Investigatorsreported today that Soliris(TM) (eculizumab), a new treatment forparoxysmal nocturnal hemoglobinuria (PNH) developed by AlexionPharmaceuticals, Inc. , is effective in patients diagnosed with PNHwho have a history of aplastic anemia (AA) or myelodysplasticsyndromes (MDS). Soliris...

Promising Results with Epratuzumab and Chemotherapy in Children with Acute Lymphoblastic Leukemia

- Results from a Children's Oncology Group (COG) Study Presented atAmerican Society of Clinical Oncology Annual Meeting - CHICAGO, June 04, 2007 /PRNewswire-FirstCall/ -- Immunomedics,Inc. , a biopharmaceutical company focused on developing monoclonalantibodies to treat cancer and other serious diseases, todayannounced that treatment with epratuzumab plus standardchemotherapy is feasible...

Study Continues to Show Patients With Myelodysplastic Syndromes Treated With Revlimid are Living Longer and Remaining Transfusion Independent

Moffitt Research Presented at 9th International Symposium onMyelodysplastic Syndromes TAMPA, Fla., May 17, 2007 /PRNewswire/ -- New updated resultsfrom a pivotal Phase II trial evaluating Revlimid in patients withan incurable blood cancer known as myelodysplastic syndromes (MDS)were presented today by Dr. Alan List, from the H. Lee MoffittCancer Center & Research Institute, at the 9th...

2007 ASCO Annual Meeting: Clinical Results on Phase IIb-study with AP 12009 in Anaplastic Astrocytoma selected for Poster Discussion

REGENSBURG, Germany, May 10th, 2007 - AntisensePharma, a German biopharmaceutical company specialized in targetedtherapies for malignant tumors, today announced, that data from thePhase IIb-study with AP 12009 in high-grade glioma will bepresented at the 43rd Annual Meeting of the American Society ofClinical Oncology (ASCO), which will be held in Chicago, Illinois,U.S.A, fro...

Once-yearly Reclast Significantly Reduced Bone Fractures in Women with Postmenopausal Osteoporosis

- Study of over 7,700 women published today shows reduction of 70percent in spine fractures and 41 percent in hip fractures EAST HANOVER, N.J., May 02, 2007 /PRNewswire/ -- A once-yearlytreatment of Reclast(R) (zoledronic acid) Injection significantlyreduced the incidence of all types of osteoporotic bone fracturesover three years in women with postmenopausal osteoporosis. Thisstudy, publ...

Flu Vaccine Used Last Winter Seems to Have Been Less Effective Than Vaccines Used in Previous Years

ROCHESTER, N.Y., May 02, 2007 /PRNewswire/ -- A new Harris Pollsuggests that the flu vaccine used before last winter may have beenless effective than the vaccines used in some previous years. Theadults who had flu shots before last winter were only 24 percentless likely to get the flu than those who were not vaccinated. Thedifferences were larger in two previous Harris Polls on the samet...

ArteFill 5-Year Data to Be Presented at American Society for Aesthetic Plastic Surgery Annual Meeting

SAN DIEGO--(BUSINESS WIRE)--Apr 17, 2007 - Artes Medical, Inc.(Nasdaq:ARTE), a medical technology company focused on developing,manufacturing and commercializing a new category of aestheticinjectable products for men and women, today announced that thefinal 5-year safety and efficacy data for ArteFill(R), theCompany's FDA-approved non-resorbable injectable dermal filler willbe presented at...

Increasing Proportion of Cardiovascular Disease Due to Diabetes Over the Last 50 Years

BETHESDA, Md., March 27, 2007--A new study shows that as ratesof diabetes have risen in the U.S., the proportion ofcardiovascular disease (CVD) linked to diabetes has alsoincreased. These findings emphasize the need for increased efforts toprevent diabetes and to aggressively treat and control CVD riskfactors among those with diabetes, according to the investigatorsfrom the long-s...

Researchers Use Poliovirus to Destroy Neuroblastoma Tumors in Mice

PHILADELPHIA, March 15, 2007-- The cause of one notoriouschildhood disease, poliovirus, could be used to treat the ongoingthreat of another childhood disease, neuroblastoma. In the March 15issue of Cancer Research, researchers from Stony Brook Universityreport that an attenuated -- or non-virulent -- form of poliovirusis effective in obliterating neuroblastoma tumors in mice, evenwhen th...